Step Therapy
Topical Agents for Atopic Dermatitis

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

NPF Coverage Policy

Drugs Affected:
- Elidel® (pimecrolimus 1% cream)
- Eucrisa® (crisaborole 2% ointment)
- Protopic® (tacrolimus 0.03% and 0.1% ointment)

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Step 1: prescription topical corticosteroids (brand or generic)

Step 2: Elidel, generic pimecrolimus 1% cream, Eucrisa, Protopic, generic tacrolimus ointment (0.03% and 0.1% strengths)

Cigna covers Step 2 agents as medically necessary when the following criteria are met:
1. If the individual has tried a Step 1 Product, approve a Step 2 Product.

2. If the individual has a dermatologic condition on or around the face, eyes/eyelids, axilla, or genitalia, approve a Step 2 Product.

3. If the individual is < 2 years of age, approve Eucrisa.

**Conditions Not Covered**

Any other exception is considered not medically necessary.

---

**Background**

**Overview**

Tacrolimus ointment and pimecrolimus cream are topical calcineurin inhibitors (immunomodulators) indicated as second-line therapy for the short-term and non-continuous chronic treatment of atopic dermatitis in non-immunocompromised patients who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Tacrolimus ointment is indicated for moderate to severe atopic dermatitis while pimecrolimus cream is indicated for mild to moderate atopic dermatitis. Tacrolimus 0.03% ointment and pimecrolimus cream are indicated in adults and children ≥ 2 years of age. Although there are data documenting the tacrolimus 0.1% strength’s safety and efficacy in children, this product is not approved for use in pediatric patients. Neither tacrolimus ointment nor pimecrolimus cream are indicated for use in children < 2 years of age; however, both agents have been studied in this patient population. Eucrisa, a phosphodiesterase 4 inhibitor, is indicated for the topical treatment of mild to moderate atopic dermatitis in patients ≥ 3 months of age. Topical corticosteroids are generally indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

**Guidelines**

According to the 2012 Joint Task Force (American Academy of Allergy, Asthma, and Immunology [AAAAI], the American College of Allergy, Asthma, and Immunology [ACAAI], and the Joint Council of Allergy, Asthma, and Immunology [JCAAI]) Atopic Dermatitis Practice Parameter and the 2014 American Academy of Dermatology (AAD) Guidelines of Care for the Management of Atopic Dermatitis make similar recommendations with regard to the topical treatment of atopic dermatitis. Moisturizers should be recommended as first-line therapy. For disease that is not controlled by moisturizers alone, a topical corticosteroid should be used, with the exception that potent fluorinated corticosteroids should not be used on the face, eyelids, genitalia, and intertriginous areas or in young infants. A low-potency corticosteroid preparation is generally recommended for these areas. The Joint Task Force practice parameter notes that tacrolimus ointment should be considered for atopic that is unresponsive to low-potency topical steroids. Tacrolimus ointment, unlike topical glucocorticoids, is not atrophogenic and has a greater therapeutic margin of safety than medium-strength corticosteroids for facial and eyelid eczema. Tacrolimus 0.1% ointment should be considered first-line therapy for facial eczema where treatment with corticosteroids is limited to low-potency corticosteroids due to safety concerns. According to guidelines, pimecrolimus cream is also efficacious and does not cause skin atrophy. The AAD guidelines confirm that both of the topical immunomodulators are effective for acute and chronic AD treatment, especially in patients with steroid-refractory atopic dermatitis, atopic dermatitis in sensitive areas (e.g., face, genitalia, skin folds), steroid-induced atrophy, and long-term uninterrupted topical steroid use. Neither the Joint Practice Parameter nor the AAD guidelines have been updated to address Eucrisa.

**References**


### Last Revision Details

| Annual Revision | No changes to criteria. | 11/11/2020 |

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.